Table 2.
Short-term treatment of T1DM NOD mice with triple RPM + IL-2.Ig + mutIL-15.Ig therapy treatment specifically restores immune tolerance to self-beta cells
| Group | Donor | Recipient | Treatment | Graft survival, days* |
|---|---|---|---|---|
| A | NOD/SCID | NOD-sp | None | 4, 7, 8, 10, 12, 21 |
| B | NOD/SCID | NOD-sp | Triple therapy | >150†, >200 × 4 |
| C | NOD/SCID | NOD-sp/stz | None | >100 × 5 |
| D | C57BL/6 | NOD-sp/stz | None | 29, 29, 30, 30, 34 |
A streptozotocin-induced diabetic state (NOD-sp/stz) was induced in NOD recipients. Spontaneously diabetic NOD mice (NOD-sp; groups B and C) were previously restored to a euglycemic state by triple-therapy treatment. These mice remained euglycemic for 230–330 days after the cessation of treatment. Syngeneic NOD/SCID islet (groups A, B, and C) or allogeneic C57BL/6 (group D) islet grafts were transplanted into NOD recipients.
*Numbers indicate survival data for individual animals in each group (six in A, five each in B, C, and D).
†Islet graft removed at >150 days.